Other than that, a pooled analysis of three trials showed that specific mutation in KRAS codon 12 also had different impact on treatment efficacy in colorectal cancer patients and tumor bearing a KRAS G12D mutation showed a strong trend to a more favorable outcome comparing to other codon 12 mutations [12] .
← all excerpts
Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.
1
—
—